Genmab A/S
GMABNext catalyst
Epcoritamab
Diffuse Large B-Cell Lymphoma
Get an email about GMAB's next catalysts
Track Genmab A/S (GMAB) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 10 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline
11 upcoming, 1 past
Epcoritamab Phase 2 Est. Readout
Primary completion for Epcoritamab trial (NCT05451810) in Diffuse Large B-Cell Lymphoma
SourceEpcoritamab Phase 2 Est. Readout
Estimated primary completion for Epcoritamab trial (NCT06510491) in Waldenstrom Macroglobulinemia. Topline data typically follows completion by weeks to months.
SourceEpcoritamab Phase 2 Est. Readout
Estimated primary completion for Epcoritamab trial (NCT06510361) in Lymphoma. Topline data typically follows completion by weeks to months.
SourceVincristine Phase 3 Est. Readout (EPCORE DLBCL-2)
Estimated primary completion for Vincristine trial (NCT05578976) in Diffuse Large B-Cell Lymphoma. Topline data typically follows completion by weeks to months.
SourceEpcoritamab Phase 2 Est. Readout
Estimated primary completion for Epcoritamab trial (NCT07108998) in CLL/SLL. Topline data typically follows completion by weeks to months.
SourceAcasunlimab Phase 3 Est. Readout
Estimated primary completion for Acasunlimab trial (NCT06635824) in PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC. Topline data typically follows completion by weeks to months.
SourceEpcoritamab Phase 2 Est. Readout
Estimated primary completion for Epcoritamab trial (NCT06536049) in Recurrent Diffuse Large B-Cell Lymphoma. Topline data typically follows completion by weeks to months.
SourceRina-S Phase 3 Est. Readout (RAINFOL-02)
Estimated primary completion for Rina-S trial (NCT07604766) in Platinum-resistant Ovarian Cancer. Topline data typically follows completion by weeks to months.
SourceHow GMAB's past catalysts played out
Market Overview
Stock performance and key metrics
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, Genmab K.K. in Tokyo, Japan, Genmab Germany GmbH in München, Germany and Genmab (Suzhou) Co., Ltd. in Suzhou, China. Genmab is listed on the Copenhagen Stock Exchange in Denmark, with American depositary receipts traded on the NASDAQ in the US.
WebsiteLeucovorin (Calcium Folinate)
Colorectal Cancer
tisotumab vedotin
Solid Tumor
Zalutumumab
Head and Neck Cancer
Epcoritamab
Diffuse Large B-Cell Lymphoma
Rina-S
Endometrial Cancer
Acasunlimab
Cutaneous Melanoma
Pegylated liposomal doxorubicin (PLD)
Platinum-resistant Ovarian Cancer
Vincristine
Follicular Lymphoma (FL)
vinorelbine
Cervical Cancer
Petosemtamab
Left-sided Colorectal Cancer
PLD
Platinum-Sensitive Ovarian Cancer
Acasunlimab in combination with docetaxel (in a single expansion cohort)
Solid Tumors
HuMax-CD4
Cutaneous T-Cell Lymphoma
Erythromycin
High Grade Epithelial Ovarian Cancer
SoC chemotherapy treatment 2
Metastatic Colorectal Cancer
Rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone
Relapsed Large B-cell Lymphoma
Investigation agent 2
Relapsed Follicular Lymphoma
CC-99282
Non-Hodgkin Lymphoma
Doxorubicin Hydrochloride
Non-Hodgkin Lymphoma
SoC chemotherapy treatment 1
Metastatic Colorectal Cancer
GDP
Large Cell Lymphoma, Diffuse
Zanubrutinib
Follicular Lymphoma
Loncastuximab Tesirine
Large B-cell Lymphoma
gemcitabine and oxaliplatin
Diffuse Large B-Cell Lymphoma
GEN1042
Malignant Solid Tumor
rituximab, ifosfamide, carboplatin, and etoposide phosphate
Diffuse Large B-Cell Lymphoma
Rituximab combined with cyclophosphamide, vincristine, and prednisone
Relapsed Large B-cell Lymphoma
Epcoritamab (maintenance)
Diffuse Large B Cell Lymphoma
Epcoritamab (monotherapy)
Diffuse Large B Cell Lymphoma
Rituximab combined with polatuzumab, cyclophosphamide, doxorubicin, and prednisone
Relapsed Large B-cell Lymphoma
Enapotamab vedotin (HuMax-AXL-ADC)
Ovarian Cancer
GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells
Breast Cancer, Breast Neoplasms
Investigation agent 3
Relapsed Follicular Lymphoma
GEN1286
Advanced Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Leucovorin (Calcium Folinate) | Phase 3 | Colorectal Cancer | - | - |
tisotumab vedotin | Phase 3 | Solid Tumor | - | - |
Zalutumumab | Phase 3 | Head and Neck Cancer | - | - |
Epcoritamab | Phase 3 | Diffuse Large B-Cell Lymphoma | - | - |
Rina-S | Phase 3 | Endometrial Cancer | - | - |
Acasunlimab | Phase 3 | Cutaneous Melanoma | - | - |
Pegylated liposomal doxorubicin (PLD) | Phase 3 | Platinum-resistant Ovarian Cancer | - | - |
Vincristine | Phase 3 | Follicular Lymphoma (FL) | - | - |
vinorelbine | Phase 3 | Cervical Cancer | - | - |
Petosemtamab | Phase 3 | Left-sided Colorectal Cancer | - | - |
PLD | Phase 3 | Platinum-Sensitive Ovarian Cancer | - | - |
Acasunlimab in combination with docetaxel (in a single expansion cohort) | Phase 2 | Solid Tumors | - | - |
HuMax-CD4 | Phase 2 | Cutaneous T-Cell Lymphoma | - | - |
Erythromycin | Phase 2 | High Grade Epithelial Ovarian Cancer | - | - |
SoC chemotherapy treatment 2 | Phase 2 | Metastatic Colorectal Cancer | - | - |
Rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone | Phase 2 | Relapsed Large B-cell Lymphoma | - | - |
Investigation agent 2 | Phase 2 | Relapsed Follicular Lymphoma | - | - |
CC-99282 | Phase 2 | Non-Hodgkin Lymphoma | - | - |
Doxorubicin Hydrochloride | Phase 2 | Non-Hodgkin Lymphoma | - | - |
SoC chemotherapy treatment 1 | Phase 2 | Metastatic Colorectal Cancer | - | - |
GDP | Phase 2 | Large Cell Lymphoma, Diffuse | - | - |
Zanubrutinib | Phase 2 | Follicular Lymphoma | - | - |
Loncastuximab Tesirine | Phase 2 | Large B-cell Lymphoma | - | - |
gemcitabine and oxaliplatin | Phase 2 | Diffuse Large B-Cell Lymphoma | - | - |
GEN1042 | Phase 2 | Malignant Solid Tumor | - | - |
rituximab, ifosfamide, carboplatin, and etoposide phosphate | Phase 2 | Diffuse Large B-Cell Lymphoma | - | - |
Rituximab combined with cyclophosphamide, vincristine, and prednisone | Phase 2 | Relapsed Large B-cell Lymphoma | - | - |
Epcoritamab (maintenance) | Phase 2 | Diffuse Large B Cell Lymphoma | - | - |
Epcoritamab (monotherapy) | Phase 2 | Diffuse Large B Cell Lymphoma | - | - |
Rituximab combined with polatuzumab, cyclophosphamide, doxorubicin, and prednisone | Phase 2 | Relapsed Large B-cell Lymphoma | - | - |
Enapotamab vedotin (HuMax-AXL-ADC) | Phase 2 | Ovarian Cancer | - | - |
GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells | Phase 2 | Breast Cancer, Breast Neoplasms | - | - |
Investigation agent 3 | Phase 2 | Relapsed Follicular Lymphoma | - | - |
GEN1286 | Phase 2 | Advanced Solid Tumor | - | - |
follicular lymphoma
1 drug in this indication
First-line head and neck squamous cell carcinoma (HNSCC)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Genmab A/S's drug pipeline?→
CatalystAlert tracks 34 drug candidates in Genmab A/S's (GMAB) pipeline across Phase 3, Phase 2. Its lead program is Epcoritamab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Genmab A/S's next FDA catalyst?→
Genmab A/S's (GMAB) next tracked catalyst is a Phase 2 readout expected March 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GMAB biotech catalysts?→
Add GMAB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Genmab A/S's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
